No relief to Neon labs to discontinuation of Local Anesthetic Lidocain - Video
|
Overview
In a setback to Neon Laboratories, the National Pharmaceutical Pricing Authority (NPPA) has rejected the drug maker's plea to discontinue scheduled formulation Lox 5% Ointment (Lidocaine 5%).
This came in response to the form-IV intimation received from Neon Laboratories Limited for discontinuation of scheduled formulation viz., Lox 5% Ointment (Lidocaine 5%) under Para 21(2) of DPCO, 2013.
For more details, check out the full story on the link below:
Setback: NPPA Panel Rejects Neon Labs Plea To Discontinue Local Anesthetic Lidocaine
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
